Depot medroxyprogesterone acetate and breast cancer: a systematic review

CONCLUSION: There is little evidence that DMPA may increase the overall risk for breast cancer. However, the incidence of breast cancer is possibly increased in current and more recent users, especially in women younger than 35 years. Long-term use did not result in any risk increase. Nevertheless, further studies will be necessary to confirm these findings and weigh up the individual risks and benefits of this contraceptive method.PMID:37966517 | DOI:10.1007/s00404-023-07265-5
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research